Achieve "Meaningful Use" of EHR Regardless of the TechnologyThe Centers for Medicare & Medicaid Services (CMS) recently released the
proposed rule defining "meaningful use" criteria for certified
electronic health records. Hospitals must have three months of data
using an EHR system in order to qualify for initial incentives by 2011.
Health systems that do not meet the criteria for meaningful use by 2015
will be penalized, and not receive their full Medicaid or Medicare
program fee schedules.
One of the challenges facing hospitals in certification is the potential
gaps in data because of inefficient workflow processes. PHS'
multi-disciplinary team of consultants is positioned to assist hospitals
in evaluating and implementing workflow processes. The Rapid Clinical
Adoption uses unique methodologies and processes that have been
successfully used in hospitals to improve patient outcomes, no matter
what type of technology is in place.
"Our proven rapid implementation methodology has assisted organizations
across the country increase efficiencies and safety while driving down
cost in a timely manner," said Rick Roycroft, group vice president,
Pharmacy Healthcare Solutions. "It is paramount that hospital executives
address process and workflow challenges as they strive to implement EHR
systems. They must maintain patient safety, address process and workflow
challenges while controlling costs. Our team works with them to
implement the ideal future state."
The Pharmacy Healthcare Solutions' team takes a multi-disciplinary
approach to look at clinical and operations improvement. The Rapid
Clinical Adoption approach helps the health systems identify gaps and
implement a plan to achieve their maximum benefit. More information
about the Rapid Clinical Adoption approach can be found by calling
877-892-1254.
About Pharmacy Healthcare Solutions,
Ltd.
Pharmacy Healthcare Solutions, Ltd.(PHS), a business unit of
AmerisourceBergen Drug Corporation, is one of the nation's largest
health system-dedicated consulting entities. The management team
provides cost savings, patient safety and strategic business growth
support to hospitals and alternate care organizations. For more
information, visit www.pharmhs.com.
About AmerisourceBergen
AmerisourceBergen Drug Corporation is a subsidiary of the
AmerisourceBergen Corporation (NYSE:ABC) that handles pharmaceutical
distribution and its related services. AmerisourceBergen is one of the
world's largest pharmaceutical services companies with operations
primarily in the United States, Canada. Servicing both healthcare
providers and pharmaceutical manufacturers in the pharmaceutical supply
channel, the Company provides drug distribution and related services
designed to reduce costs and improve patient outcomes.
AmerisourceBergen's service solutions range from pharmacy automation and
pharmaceutical packaging to reimbursement and pharmaceutical consulting
services. With more than $71 billion in annual revenue,
AmerisourceBergen is headquartered in Valley Forge, PA, and employs
approximately 10,000 people. AmerisourceBergen is ranked #26 on the
Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. These statements are based on management's current expectations
and are subject to uncertainty and change in circumstances. Among the
factors that could cause actual results to differ materially from those
projected, anticipated or implied are the following: changes in
pharmaceutical market growth rates; the loss of one or more key customer
or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other dispute with customers or suppliers; federal and state
government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled
substances; qui tam litigation for alleged violations of laws and
regulations governing the marketing, sale and purchase of pharmaceutical
products; changes in U.S. legislation or regulatory action affecting
pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare; changes in regulatory or clinical medical
guidelines and/or labeling for the pharmaceutical products we
distribute, including certain anemia products; price inflation in
branded pharmaceuticals and price deflation in generics; significant
breakdown or interruption of our information technology systems; our
inability to implement an enterprise resource planning (ERP) system to
handle business and financial processes within AmerisourceBergen Drug
Corporation's operations and our corporate functions without operating
problems and/or cost overruns; success of integration, restructuring or
systems initiatives; interest rate and foreign currency exchange rate
fluctuations; economic, business, competitive and/or regulatory
developments in Canada, the United Kingdom and elsewhere outside of the
United States, including potential changes in Canadian provincial
legislation affecting pharmaceutical product pricing or service fees or
regulatory action by provincial authorities in Canada to lower
pharmaceutical product pricing or service fees; the impact of
divestitures or the acquisition of businesses that do not perform as we
expect or that are difficult for us to integrate or control; our
inability to successfully complete any other transaction that we may
wish to pursue from time to time; changes in tax legislation or adverse
resolution of challenges to our tax positions; increased costs of
maintaining, or reductions in our ability to maintain, adequate
liquidity and financing sources; volatility and deterioration of the
capital and credit markets; and other economic, business, competitive,
legal, tax, regulatory and/or operational factors affecting our business
generally. Certain additional factors that management believes could
cause actual outcomes and results to differ materially from those
described in forward-looking statements are set forth (i) in Item 1A
(Risk Factors) in the Company's Annual Report on Form 10-K for this
Fiscal Year Ended September 30, 2009 and elsewhere in that report and
(ii) in other reports filed by the Company pursuant to the Securities
Exchange Act of 1934.
SOURCE: AmerisourceBergen Drug Corporation
AmerisourceBergen
Nora Beger, 610-727-2384
[email protected]